Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06948591 · ClinicalTrials.gov registry record
BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures
A clinical trial of ACL Tears, sponsored by CONMED Corporation.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06948591: Recruiting study of ACL Tears, sponsored by CONMED Corporation.
NCT06948591 is a study of ACL Tears that is actively recruiting participants, run by CONMED Corporation. The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06948591, a study of ACL Tears, is actively recruiting participants, sponsored by CONMED Corporation.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.
Primary Outcome
Improvement in function measured with International Knee Documentation Committee (IKDC) from baseline to 3 years post-surgery.
Conditions Studied
Interventions
- DEVICE Anterior cruciate ligament reconstruction with BioBrace® augmentation
- PROCEDURE Arthroscopic anterior cruciate ligament reconstruction
Study Locations (1)
Connecticut
- ConMed - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2030-06 |
What NCT06948591 shows while recruiting
NCT06948591 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with ACL Tears appearing as the primary indexed condition, and to 2 interventions - of which Anterior cruciate ligament reconstruction with BioBrace® augmentation is the first listed.
NCT06948591 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06948591 about?
NCT06948591 is a clinical study titled "BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures". This research study will evaluate mid-term clinical safety and performance outcomes of the BioBrace® Reinforced Implant when used to augment a tissue graft during anterior cruciate ligament (ACL) reconstruction.
What is the current status of trial NCT06948591?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-04-08. Estimated completion is 2030-06.
What conditions does trial NCT06948591 study?
This clinical trial studies the following conditions: ACL Tears.
What interventions are being tested in trial NCT06948591?
The interventions under investigation include: Anterior cruciate ligament reconstruction with BioBrace® augmentation (DEVICE), Arthroscopic anterior cruciate ligament reconstruction (PROCEDURE).
Who is sponsoring clinical trial NCT06948591?
This trial is sponsored by CONMED Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06948591 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI